Free Trial

Dave Weiner Analyst Performance

Analyst at Piper Sandler

Dave Weiner is a stock analyst at Piper Sandler focused in the consumer discretionary sector, covering 9 publicly traded companies. Over the past year, Dave Weiner has issued 1 stock ratings, including and buy recommendations. While full access to Dave Weiner's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Dave Weiner's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
86 Last 11 Years
Buy Recommendations
75.00% 63 Buy Ratings
Companies Covered
9 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy75.0%63 ratings
Hold25.0%21 ratings
Sell0.0%0 ratings

Out of 84 total stock ratings issued by Dave Weiner at Piper Sandler, the majority (75.0%) have been Buy recommendations, followed by 25.0% Hold.

Exchange Coverage

ExchangePercentageCount
NYSE
77.8% of companies on NYSE
7 companies
NASDAQ
22.2% of companies on NASDAQ
2 companies

Dave Weiner, an analyst at Piper Sandler, currently covers 9 companies listed on NYSE and NASDAQ, with the majority traded on NYSE.

Coverage Focus

Sector IconSectorPercentage
Consumer Discretionary
6 companies
66.7%
Retail/Wholesale
2 companies
22.2%
Medical
1 company
11.1%

Dave Weiner of Piper Sandler specializes in stock coverage within the Consumer Discretionary sector, with additional focus on Retail/Wholesale and Medical companies.

Coverage Industries

IndustryPercentage
TEXTILE - APPAREL
5 companies
55.6%
RETAIL - APP/SHOE
2 companies
22.2%
MED - BIOMED/GENE
1 company
11.1%
SHOES&REL APPRL
1 company
11.1%

Dave Weiner's Ratings History at Piper Sandler

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
11/11/2025Lower Price Target$6.66$8.50Overweight
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
3/12/2025Upgrade$10.25$12.50Overweight
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
3/4/2025Lower Price Target$10.35$11.50Neutral